Dr. Hönle Forecast, price target & analysts
Dr. Hönle Target price 2026 - Analyst rating & recommendation
Dr. Hönle Classifications & Recommendation
Dr. Hönle Price Target
| Target Price | €17.34 |
| Price | €7.48 |
| Potential |
131.82%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Dr. Hönle 2027 .
The average Dr. Hönle target price is €17.34.
This is
131.82%
register free of charge
€18.90
152.67%
register free of charge
€14.14
89.04%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Dr. Hönle to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Dr. Hönle stock has an average upside potential 2027 of
131.82%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million € | 93.68 | 94.54 |
| 5.11% | 0.91% | |
| EBITDA Margin | 5.65% | 6.37% |
| 46.33% | 12.81% | |
| Net Margin | -3.38% | -1.29% |
| 74.84% | 61.88% |
4 Analysts have issued a sales forecast Dr. Hönle 2026 . The average Dr. Hönle sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Dr. Hönle EBITDA forecast 2026. The average Dr. Hönle EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Dr. Hönle Analysts have issued a net profit forecast 2026. The average Dr. Hönle net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | -0.52 | -0.20 |
| 76.26% | 61.54% | |
| P/E | negative | |
| EV/Sales | 0.90 |
4 Analysts have issued a Dr. Hönle forecast for earnings per share. The average Dr. Hönle EPS is
This results in the following potential growth metrics and future valuations:
Current Dr. Hönle Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| NUWAYS AG |
Locked
➜
Locked
|
Locked | Aug 19 2026 |
| MWB RESEARCH AG |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | May 21 2026 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | May 20 2026 |
| NUWAYS AG |
Locked
➜
Locked
|
Locked | May 20 2026 |
| NUWAYS AG |
Locked
➜
Locked
|
Locked | May 19 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
NUWAYS AG:
Locked
➜
Locked
|
Aug 19 2026 |
|
Locked
MWB RESEARCH AG:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
May 21 2026 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
May 20 2026 |
|
Locked
NUWAYS AG:
Locked
➜
Locked
|
May 20 2026 |
|
Locked
NUWAYS AG:
Locked
➜
Locked
|
May 19 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
